A Randomized Double-Blind Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

    Not Recruiting
  • participants needed
  • sponsor
    Satsuma Pharmaceuticals, Inc.
Updated on 16 June 2021
Clinical Trial Manager
Primary Contact
Medvadis Research Group (0.4 mi away) Contact
+123 other location
acute treatment


Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine


The EMERGE trial is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in subjects with acute migraine (ages 18 to 65 years).

Condition Migraine, Migraine with Aura, Common Migraine, Primary Stabbing Headache, Migraine (Adult), Migraine and Cluster Headaches, Migraine (Pediatric)
Treatment placebos, Dihydroergotamine, Dihydroergotamine
Clinical Study IdentifierNCT03901482
SponsorSatsuma Pharmaceuticals, Inc.
Last Modified on16 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note